このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

AlzeCure Pharma マネジメント

マネジメント基準チェック /34

AlzeCure Pharma'sの CEO はMartin Jönssonで、 Jan2020年に任命され、の在任期間は 4.42年です。の年間総報酬はSEK 2.48Mで、 76.6%給与と23.4%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.66%を直接所有しており、その価値はSEK 773.89K 。経営陣と取締役会の平均在任期間はそれぞれ4.4年と3.1年です。

主要情報

Martin Jönsson

最高経営責任者

kr2.5m

報酬総額

CEO給与比率	76.6%
CEO在任期間	4.4yrs
CEOの所有権	0.7%
経営陣の平均在職期間	4.4yrs
取締役会の平均在任期間	3.1yrs

経営陣の近況

Recent updates

Need To Know: AlzeCure Pharma AB (publ) (STO:ALZCUR) Insiders Have Been Buying Shares

Feb 03

We're Not Very Worried About AlzeCure Pharma's (STO:ALZCUR) Cash Burn Rate

Dec 13

CEO報酬分析

AlzeCure Pharma の収益と比較して、Martin Jönsson の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-kr37m
Dec 31 2023	kr2m	kr2m	-kr37m
Sep 30 2023	n/a	n/a	-kr38m
Jun 30 2023	n/a	n/a	-kr42m
Mar 31 2023	n/a	n/a	-kr53m
Dec 31 2022	kr2m	kr2m	-kr56m
Sep 30 2022	n/a	n/a	-kr68m
Jun 30 2022	n/a	n/a	-kr73m
Mar 31 2022	n/a	n/a	-kr67m
Dec 31 2021	kr2m	kr2m	-kr78m
Sep 30 2021	n/a	n/a	-kr73m
Jun 30 2021	n/a	n/a	-kr78m
Mar 31 2021	n/a	n/a	-kr81m
Dec 31 2020	kr2m	kr1m	-kr71m

報酬と市場: Martinの総報酬 ($USD 237.18K ) は、 Swedish市場 ($USD 257.78K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Martinの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Martin Jönsson (56 yo)

4.4yrs

在職期間

kr2,475,000

報酬

Mr. Martin Jönsson is the Chief Executive Officer of AlzeCure Pharma AB (publ) since January 8, 2020. Mr. Jönsson served in a senior position at Ferring Pharmaceuticals in the US, he was business area dire...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Martin Jönsson	Chief Executive Officer	4.4yrs	kr2.48m	0.66% SEK 767.7k
Birgitta Lundvik	Chief Financial Officer	7.4yrs	データなし	0.20% SEK 229.7k
Johan Sandin	Chief Scientific Officer	4.4yrs	kr1.28m	1.41% SEK 1.6m
Marta Storck	Chief Medical Officer & Head of Development	3.2yrs	データなし	0.12% SEK 139.1k
Pontus Forsell	Head of Research & Discovery	7.4yrs	データなし	1.46% SEK 1.7m

4.4yrs

平均在職期間

57yo

平均年齢

経験豊富な経営陣: ALZCURの経営陣は経験豊富であると考えられます ( 4.4年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Thomas Pollare	Chairman	7.4yrs	kr229.00k	2.42% SEK 2.8m
Jan Lundberg	Director	less than a year	データなし	データなし
Ragnar Linder	Independent Director	7.4yrs	kr115.00k	0.080% SEK 93.2k
John Harrison	Scientific Advisor	no data	データなし	データなし
Bengt Winblad	Scientific Advisor	no data	データなし	データなし
Peter Snyder	Scientific Advisor	no data	データなし	データなし
Henrik Zetterberg	Scientific Advisor	no data	データなし	データなし
Rolf Karlsten	Scientific Advisor	no data	データなし	データなし
Janet Hoogstraate	Independent Director	1.1yrs	kr73.00k	0.040% SEK 46.9k
Sven Ogren	Scientific Advisor	no data	データなし	データなし
Eva Lilienberg	Independent Director	3.1yrs	kr115.00k	0.0040% SEK 4.7k

3.1yrs

平均在職期間

70yo

平均年齢

経験豊富なボード: ALZCURの取締役会は経験豊富であると考えられます ( 3.1年の平均在任期間)。

AlzeCure Pharma マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

AlzeCure Pharma AB (publ) Approves the Election of Jan Lundberg as New Ordinary Members of the Board of Directors

AlzeCure Pharma AB (publ) Approves the Election of Jan Lundberg as New Ordinary Members of the Board of Directors

AlzeCure Pharma AB (publ) Appoints Janet Hoogstraate to its Board

AlzeCure Pharma AB (publ), Annual General Meeting, May 17, 2023

Chief Executive Officer recently bought kr163k worth of stock

Chief Executive Officer recently bought kr163k worth of stock

Recent updates

Alzecure Pharma AB (Publ) Announces Positive Clinical Results with Painless ACD440 Against Neuropathic Pain

AlzeCure Pharma AB (publ) Approves the Election of Jan Lundberg as New Ordinary Members of the Board of Directors

AlzeCure Pharma AB (publ) Approves the Election of Jan Lundberg as New Ordinary Members of the Board of Directors

Price target decreased by 10% to kr13.00

AlzeCure Pharma AB (publ) Presents New Data Regarding the TrkA-NAM Pain Project at IASP 2024

New major risk - Market cap size

AlzeCure Pharma AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 52.77396 million.

AlzeCure Presents New Preclinical Data with NeuroRestore ACD856 at Leading Alzheimer's Conference

AlzeCure Pharma AB (publ) Publishes Clinical Results Supporting Continued Development of NeuroRestore ACD856 Against Alzheimer's

New minor risk - Share price stability

AlzeCure Pharma AB (publ) Gets Late Breaking Abstract of New Preclinical Data with ACD856 Accepted at AD/PD 2024 Conference

AlzeCure Pharma AB (publ) Selects Drug Candidate and Enters Next Phase of Development with Trka-Nam Acd137 Against Severe Pain

We Think AlzeCure Pharma (STO:ALZCUR) Can Afford To Drive Business Growth

AlzeCure Pharma AB (publ) Presents Disease-Modifying Data with NeuroRestore ACD856 At Alzheimer's Conference CTAD

AlzeCure Pharma AB (publ) Announces Japenese Patent Office Grants Patent Covering its Leading Candidate Drug ACD856

Alzecure Presents Clinical Phase Ii-Data with Acd440 for Neuropathic Pain At Pain Conference

AlzeCure Gets Presentation Accepted on Disease-Modifying Effects of Acd856 At Alzheimer's Conference

AlzeCure Pharma AB (publ) Presents Positive Phase II Clinical Data with ACD440 Against Neuropathic Pain at EFIC 2023 Conference

AlzeCure Pharma AB (publ) to Report Fiscal Year 2023 Final Results on Apr 04, 2024

New minor risk - Financial position

AlzeCure Pharma AB (publ) to Report Q4, 2023 Results on Feb 27, 2024

AlzeCure Pharma Publishes the Positive Clinical Results from the Phase I Trial of NeuroRestore ACD856 Against Alzheimer's

Companies Like AlzeCure Pharma (STO:ALZCUR) Can Afford To Invest In Growth

AlzeCure Pharma AB (Publ) Publishes New Disease Modifying Data with Neurorestore ACD856 Against Alzheimer's and Cognitive Disorders

Alzecure Announces Positive Phase IIa Clinical Study Data in Neuropathic Pain with the Non-Opioid ACD440

AlzeCure Pharma AB (publ) Appoints Janet Hoogstraate to its Board

Forecast to breakeven in 2025

Last Patient Included in Alzecure's Phase II Clinical Trial in Peripheral Neuropathic Pain with The Non-Opioid ACD440

AlzeCure Pharma AB (publ) Selects CD and Enters Next Development Phase with Alzstatin ACD680 against Alzheimer's

Alzecure Pharma AB (Publ) Gets Abstract Accepted on New Potential Disease-Modifying Effects of ACD856 Against Alzheimer's

AlzeCure Pharma AB (publ) Gets Late-Breaking Abstract on New Data with Alzheimer Project

Alzecure Pharma AB (Publ) Announces New Data on Alzstatin for Preventive Treatment Against Alzheimer's Presented At Alzheimer's Conference CTAD

Alzheimer Announces New Data Strengthening the Continued Clinical Development of NeuroRestore ACD856

Price target decreased to kr12.00

AlzeCure Pharma AB (publ) Gets Abstract Accepted on Positive Clinical EEG Results with Alzheimer's Project NeuroRestore ACD856

Price target decreased to kr12.00

Will AlzeCure Pharma (STO:ALZCUR) Spend Its Cash Wisely?

AlzeCure Pharma AB (publ) Announces New Data from AlzeCure Demonstrate Potential Disease-Modifying Effects of NeuroRestore ACD856

AlzeCure Presents New Data on the Anti-Inflammatory Effects of its TrkA-NAM Pain Project at IASP 2022

AlzeCure's Alzheimer’s Project NeuroRestore ACD856 Shows Positive Effect on Brain Activity in Clinical Trial

AlzeCure Pharma AB (publ), Annual General Meeting, May 17, 2023

AlzeCure Pharma AB (publ) Gets Abstract Accepted on Potential Neuroprotective Effects of NeuroRestore ACD856

AlzeCure Pharma AB Gets Abstract on New Clinical Study Data with NeuroRestore Accepted At the Alzheimer's Conference Aaic

AlzeCure Pharma AB (Publ) Announces Update on Clinical Phase I Study

AlzeCure Pharma AB (publ) Announces First Patient Included in its Phase II Clinical Trial in Neuropathic Pain with Non-Opioid ACD440

Alzecure Pharma AB (Publ)'s Abstract on Pain Project TrkA-NAM Accepted for Presentation At IASP 2022

AlzeCure Pharma AB (publ) Gets Approval to Start Phase II Clinical Trial with Non-Opioid Pain Project ACD440

AlzeCure Pharma AB (publ) Publishes New Data on Alzstatin from Alzheimer Conference

AlzeCure Publishes New Data on NeuroRestore and Acd856 from Alzheimer's Conference

Chief Executive Officer recently bought kr163k worth of stock

Chief Executive Officer recently bought kr163k worth of stock

Chief Financial Officer recently bought kr120k worth of stock

Alzecure Pharma AB (Publ) Receives Positive Indicative Clinical Data with Acd856 in Development for Alzheimer's Disease

Alzecure Pharma AB (publ) Announces Moving Towards Phase IIa Clinical Trial with ACD440 Based on Guiding Response from the FDA

Is AlzeCure Pharma (STO:ALZCUR) In A Good Position To Invest In Growth?

Price target increased to kr21.90

AlzeCure Pharma AB (publ) to Present Abstract at ECNP Conference on NeuroRestore Project's Potential in Depression

Is AlzeCure Pharma (STO:ALZCUR) In A Good Position To Invest In Growth?

Is AlzeCure Pharma (STO:ALZCUR) In A Good Position To Invest In Growth?

AlzeCure Pharma AB (publ) to Report Fiscal Year 2021 Results on Feb 24, 2022

AlzeCure Pharma AB (publ) to Report Q2, 2021 Results on Aug 25, 2021

New 90-day low: kr7.50

Need To Know: AlzeCure Pharma AB (publ) (STO:ALZCUR) Insiders Have Been Buying Shares

New 90-day low: kr8.16

We're Not Very Worried About AlzeCure Pharma's (STO:ALZCUR) Cash Burn Rate

Chief Financial Officer recently bought kr96k worth of stock

Chief Financial Officer recently bought kr96k worth of stock

AlzeCure Pharma AB (publ), Annual General Meeting, May 12, 2021

AlzeCure Pharma AB (publ) Receives Approval to Start Clinical Phase I Trial with ACD856 in Alzheimer's Disease

マネジメント基準チェック /34